Withdrawal of marketing authorisation application for Janacti® (sitagliptin and pioglitazone) (European Medicines Agency, 15 November 2011)

16 Nov 2011

Merck Sharp & Dohme (Europe), Inc. has withdrawn its application to the European Medicines Agency for a centralised marketing authorisation for the medicine Janacti (sitagliptin and pioglitazone), intended for the treatment of adult patients with type 2 diabetes mellitus.